Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0KJHHN
ADC Name	IMGN-779
Synonyms	IMGN 779; IMGN779 Click to Show/Hide
Organization	ImmunoGen, Inc.
Drug Status	Clinical candidate
Indication	In total 1 Indication(s) Myelodysplastic syndrome [ICD11:2A37] Clinical candidate
Structure
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Myeloid cell surface antigen CD33 (CD33)		Antigen Info
Payload Name	DGN462		Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)		Target Info
Linker Name	Sulfo-SPDB		Linker Info

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 100	%	EoL-1 cells	Chronic eosinophilic leukemia
Tumor Growth Inhibition value (TGI)	≈ 100	%	MV4-11 cells	Childhood acute monocytic leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 15)	Positive CD33 expression (CD33+++/++)
Method Description	EOL-1 tumor-bearing mice received a single intravenous bolus administration of vehicle, IMGN779, or Ab-DGN462, with each conjugate molecule dosed at approximately 1.5 mg/kg ADC by antibody concentration (i.e., 10 or 30 ug/kg linked IGN).
In Vivo Model	EOL-1 CDX model
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 30)	Positive CD33 expression (CD33+++/++)
Method Description	IMGN779 (0.5 mg/kg, a single dose) induces efficient tumor cell killing in cell line-derived models of MV4-11 cells with CD33 expression with high expression.
In Vivo Model	MV4-11 CDX model
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

References

Ref 1	IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML. Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27.